The Impact of Immune-Related Adverse Events on the Survival of Patients Treated with Immune Checkpoint Inhibitors: The Distinct Role of Cardiac Toxicities
Authors:
- Ileana-Raluca PătruIPIleana-Raluca Pătru
- Alexandra-Valentina AnghelAAAlexandra-Valentina Anghel
- Eusebiu Robert GaleschiEGEusebiu Robert Galeschi
- Lorena Carolina BătăușLBLorena Carolina Bătăuș
- Andreea-Iuliana IonescuAIAndreea-Iuliana Ionescu
- Alina Gabriela NegruAlina Gabriela Negru
- Maria Alexandra BarbuMBMaria Alexandra Barbu
- Maria IordacheMIMaria Iordache
- Ionuț-Lucian Antone-IordacheIonuț-Lucian Antone-Iordache
Open Access
- 3 November 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7794
Abstract
Background: Immunotherapy with immune checkpoint inhibitors (ICIs) has fundamentally transformed cancer treatments. Unfortunately, its benefits are accompanied by the occurrence of immune-related adverse events (irAEs). While non-cardiac irAEs have been consistently associated with a favorable prognosis, the impact of cardiac toxicities remains insufficiently explored. Methods: We conducted a retrospective, observational study at the Oncology Department of Colțea Clinical Hospital, Bucharest. All the patients treated with ICIs between 1 May 2019 and 1 February 2024 were selected in the initial cohort. Of 512 eligible patients, 435 were included in the final analysis, with comprehensive recordings of clinical, oncological, and cardiac monitoring parameters, and at least one complete cycle of ICI treatment. Adverse events were classified according to CTCAE v5.0, and overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier estimates and Cox regression models. Results: Our results showed that patients who developed non-cardiac irAEs experienced a significant survival benefit: median OS 26.0 months (95% CI, 15.5–NA) vs. 13.9 months (95% CI, 12.4–16.5), 0.66 (95% CI, 0.49–0.9) hazard ratio (HR); median PFS 12.3 months (95% CI, 8.1–26.0) vs. 8.7 months (95% CI, 7.3–10.3), 0.74 (95% CI, 0.56–0.97) HR. Conversely, patients with cardiac toxicities did not derive the same advantage, with similar OS and PFS values that did not reach statistical significance: median OS 15.0 months (95% CI, 13.3–19.3) vs. 15.8 months (95% CI, 12.0–30.3), 1.11 (95% CI, 0.78–1.57) HR; median PFS 9.1 months (95% CI, 7.6–10.4) vs. 8.1 months (95% CI, 5.3–19.3), 1.003 (95% CI, 0.72–1.39) HR. Conclusions: These findings support the role of non-cardiac irAEs as markers of favorable therapeutic response, while cardiac irAEs do not confer the same prognostic benefit. The results underscore the importance of active cardiovascular monitoring and close multidisciplinary collaboration in the management of patients receiving ICIs.Keywords
Funding Information
- Romanian National Society of Medical Oncology
This publication has 44 references indexed in Scilit:
- Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitor-Related Myocarditis: A Large Single-Centre AnalysisESC Heart Failure, 2024
- Immune Checkpoint Inhibitor–Induced CardiotoxicityJAMA Oncology, 2024
- Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapyBasic Research in Cardiology, 2024
- Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsJAMA Network Open, 2024
- Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for CliniciansDrug Safety, 2023
- Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System databaseCancer Medicine, 2022
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With CancerJAMA Oncology, 2020
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysisJournal of Cancer Research and Clinical Oncology, 2018
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerJAMA Oncology, 2018